MedPath

Talc pleurodesis for malignant pleural effusions.

Not Applicable
Completed
Conditions
malignant pleural effusion
Registration Number
JPRN-UMIN000009175
Lead Sponsor
St. Marianna University School of Medicine
Brief Summary

Talc is considered to be acceptable in both efficacy and safety as sclerosing agent for pleurodesis also in Japanese patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

having insufficient expansion of the lung after pleural fluid drainage (having trapped lung), inadequate lung function parameters, and severe heart failure.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Efficacy. We evaluate at 30, 90, and 180 days after talc pleurodesis by chest radiography.
Secondary Outcome Measures
NameTimeMethod
Safety. We evaluated any complications requiring additional treatment or procedures within 30 days after talc pleurodesis.
© Copyright 2025. All Rights Reserved by MedPath